PRESS RELEASES
FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease
Planned to Launch in the Fourth Quarter 2015 in the United States as the First Alzheimer’s Clinical Trial Using Intravenous Administration of Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica Cell...
Stemedica Obtains an Exclusive Worldwide License for Stem Cell Stabilization and Preservation Technologies
Commercial-scale Preservation of Therapeutically-active Stem Cell-derived Products For Worldwide Marketplace Opportunities SAN DIEGO—March 24, 2015—Stemedica Cell Technologies Inc., (Stemedica), announced today that Universal Stabilization Technologies (UST) has...
Stemedica Issued US Patent Method for Identifying Neuripotent Cells
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent...
President of Leading South Korean Biopharmaceutical Company Green Cross Holdings Joins Stemedica’s Board of Directors
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross,...
Stemedica Announces New Board Member and Chairman of Audit Committee
Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014. Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He...
Stemedica Announces New Chief Financial Officer
Stemedica Cell Technologies, Inc. a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014. Craig Carlson brings 34 years of...
Stemedica Advances to Phase II Stroke Trial with Lead Product Stemedyne-MSC
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially...
Stemedica Enters into a Global Distribution Agreement with Life Technologies
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement,...